| scholarly article | Q13442814 |
| P356 | DOI | 10.1111/J.1464-5491.2010.02938.X |
| P698 | PubMed publication ID | 20536495 |
| P2093 | author name string | J-F Gautier | |
| C Filozof | |||
| P2860 | cites work | Novel combination treatment of type 2 diabetes DPP-4 inhibition + metformin | Q36812821 |
| P433 | issue | 3 | |
| P921 | main subject | metformin | Q19484 |
| gliclazide | Q290001 | ||
| type 2 diabetes | Q3025883 | ||
| P304 | page(s) | 318-326 | |
| P577 | publication date | 2010-03-01 | |
| P1433 | published in | Diabetic Medicine | Q15758639 |
| P1476 | title | A comparison of efficacy and safety of vildagliptin and gliclazide in combination with metformin in patients with Type 2 diabetes inadequately controlled with metformin alone: a 52-week, randomized study | |
| P478 | volume | 27 |
| Q35844788 | A 16-week study to compare the effect of vildagliptin versus gliclazide on postprandial lipoprotein concentrations and oxidative stress in patients with type 2 diabetes inadequately controlled with metformin monotherapy |
| Q58792938 | A comparison of the anti-diabetic potential of d-ribose-l-cysteine with insulin, and oral hypoglycaemic agents on pregnant rats |
| Q33710159 | A double-blind, randomized trial, including frequent patient-physician contacts and Ramadan-focused advice, assessing vildagliptin and gliclazide in patients with type 2 diabetes fasting during Ramadan: the STEADFAST study |
| Q37652091 | A randomized controlled clinical trial of vildagliptin plus metformin combination therapy in patients with type II diabetes mellitus |
| Q37610459 | A systematic literature review on the efficacy-effectiveness gap: comparison of randomized controlled trials and observational studies of glucose-lowering drugs |
| Q36510353 | Achievement of recommended glucose and blood pressure targets in patients with type 2 diabetes and hypertension in clinical practice - study rationale and protocol of DIALOGUE |
| Q34563587 | Achieving glycemic control in elderly patients with type 2 diabetes: a critical comparison of current options |
| Q37456636 | Addition of sulphonylurea to metformin does not relevantly change body weight: a prospective observational cohort study (ZODIAC-39). |
| Q83226453 | Are sulfonylureas less desirable than DPP-4 inhibitors as add-on to metformin in the treatment of type 2 diabetes? |
| Q42161597 | Assessing the general safety and tolerability of vildagliptin: value of pooled analyses from a large safety database versus evaluation of individual studies |
| Q28071764 | Cardiovascular Effect of Incretin-Based Therapy in Patients with Type 2 Diabetes Mellitus: Systematic Review and Meta-Analysis |
| Q40651201 | Cardiovascular and heart failure safety profile of vildagliptin: a meta-analysis of 17 000 patients |
| Q30241808 | Cardiovascular effects of dipeptidyl peptidase-4 inhibitor in diabetic patients with and without established cardiovascular disease: a meta-analysis and systematic review |
| Q43409321 | Cardiovascular safety of sulfonylureas: a meta-analysis of randomized clinical trials. |
| Q37949599 | Choosing a gliptin |
| Q91638386 | Clinical Use of DPP-4 Inhibitors |
| Q37825941 | Clinical evidence and mechanistic basis for vildagliptin's action when added to metformin |
| Q35717211 | Clinical trial simulation methods for estimating the impact of DPP-4 inhibitors on cardiovascular disease |
| Q37991385 | Combination therapy with metformin plus vildagliptin in type 2 diabetes mellitus. |
| Q33785197 | Comparative effectiveness of dipeptidylpeptidase-4 inhibitors in type 2 diabetes: a systematic review and mixed treatment comparison |
| Q28546797 | Comparative efficacy and safety of antidiabetic drug regimens added to metformin monotherapy in patients with type 2 diabetes: a network meta-analysis |
| Q38644587 | Comparative review of dipeptidyl peptidase-4 inhibitors and sulphonylureas. |
| Q92922840 | Comparison of the Effectiveness and Safety of Vildagliptin Add-On to Metformin Versus Other Oral Dual Antidiabetes Agents in Patients with Type 2 Diabetes: The China Prospective Diabetes Study |
| Q38154679 | Composite endpoints in trials of type-2 diabetes |
| Q52657004 | Consensus Recommendations on Sulfonylurea and Sulfonylurea Combinations in the Management of Type 2 Diabetes Mellitus - International Task Force. |
| Q30234836 | Cost-effectiveness of vildagliptin for people with type 2 diabetes mellitus in Brazil; findings and implications. |
| Q40487459 | DPP-4 inhibitors and risk of infections: a meta-analysis of randomized controlled trials. |
| Q38163071 | Dapagliflozin compared with other oral anti-diabetes treatments when added to metformin monotherapy: a systematic review and network meta-analysis |
| Q42175983 | Dipeptidyl Peptidase 4: A New Link between Diabetes Mellitus and Atherosclerosis? |
| Q28294225 | Dipeptidyl peptidase-4 inhibitors and pancreatitis risk: a meta-analysis of randomized clinical trials |
| Q38126945 | Dipeptidyl peptidase-4 inhibitors for the treatment of type 2 diabetes: comparison, efficacy and safety |
| Q38001085 | Effect of antidiabetic agents added to metformin on glycaemic control, hypoglycaemia and weight change in patients with type 2 diabetes: a network meta-analysis. |
| Q28067209 | Effectiveness and Safety of Newer Antidiabetic Medications for Ramadan Fasting Diabetic Patients |
| Q34726395 | Effectiveness and Tolerability of Second-Line Therapy with Vildagliptin Versus Other Oral Agents in Type 2 Diabetes (EDGE): Post Hoc Sub-Analysis of Bulgarian Data |
| Q35167496 | Effectiveness and tolerability of second-line therapy with vildagliptin versus other oral agents in type 2 diabetes (EDGE): post-hoc subanalysis of the Belgian data |
| Q34507122 | Effectiveness and tolerability of second-line therapy with vildagliptin vs. other oral agents in type 2 diabetes: a real-life worldwide observational study (EDGE) |
| Q51370472 | Effectiveness of adding vildagliptin to the treatment of diabetic patients nonresponsive to the combination of metformin and a sulphonylurea. |
| Q38100678 | Efficacy and safety of dipeptidyl peptidase-4 inhibitors in combination with metformin |
| Q51360460 | Efficacy and tolerability of vildagliptin as add-on therapy to metformin in Chinese patients with type 2 diabetes mellitus. |
| Q41598367 | Efficacy and tolerability of vildagliptin-based versus comparative dual therapy in type 2 diabetes : Results of the Austrian subpopulation of the EDGE study |
| Q43462577 | Efficacy of dipeptidyl-peptidase-4 inhibitors and impact on β-cell function in Asian and Caucasian type 2 diabetes mellitus patients: A meta-analysis |
| Q87558803 | Efficacy of vildagliptin versus sulfonylureas as add-on therapy to metformin: comparison of results from randomised controlled and observational studies |
| Q35214435 | Enhanced glycemic control with combination therapy for type 2 diabetes in primary care |
| Q38219482 | Evidence-based practice use of incretin-based therapy in the natural history of diabetes |
| Q84502134 | Gliptin versus a sulphonylurea as add-on to metformin |
| Q90201462 | Glycaemic durability of an early combination therapy with vildagliptin and metformin versus sequential metformin monotherapy in newly diagnosed type 2 diabetes (VERIFY): a 5-year, multicentre, randomised, double-blind trial |
| Q38152405 | Head-to-head comparison of dipeptidyl peptidase-IV inhibitors and sulfonylureas - a meta-analysis from randomized clinical trials |
| Q36428052 | Impact of insulin resistance, body mass index, disease duration, and duration of metformin use on the efficacy of vildagliptin |
| Q38787756 | Incretin-Based Therapy for Diabetes: What a Cardiologist Needs to Know. |
| Q38754132 | Is gliclazide a sulfonylurea with difference? A review in 2016. |
| Q38004088 | Longer term safety of dipeptidyl peptidase-4 inhibitors in patients with type 2 diabetes mellitus: systematic review and meta-analysis |
| Q93174864 | Metformin and second- or third-generation sulphonylurea combination therapy for adults with type 2 diabetes mellitus |
| Q41826517 | Minimizing the risk of hypoglycemia with vildagliptin: Clinical experience, mechanistic basis, and importance in type 2 diabetes management |
| Q50168195 | Network meta-analysis of lorcaserin and oral hypoglycaemics for patients with type 2 diabetes mellitus and obesity |
| Q35146648 | Observational and clinical trial findings on the comparative effectiveness of diabetes drugs showed agreement |
| Q30249371 | Pharmacology and therapeutic implications of current drugs for type 2 diabetes mellitus |
| Q47690129 | Prognostic implications of DPP-4 inhibitor vs. sulfonylurea use on top of metformin in a real world setting - results of the 1 year follow-up of the prospective DiaRegis registry |
| Q38718023 | Relationship Between Duration of Type 2 Diabetes and Effectiveness of DPP-4 Inhibitor Versus Sulfonylurea as Add-on Therapy: A Post Hoc Analysis |
| Q37890793 | Review of the safety and efficacy of linagliptin as add-on therapy to metformin in patients with type 2 diabetes: a randomized, double-blind, placebo-controlled study |
| Q27022613 | Safety and efficacy of gliclazide as treatment for type 2 diabetes: a systematic review and meta-analysis of randomized trials |
| Q38682317 | Systematic review and meta-analysis of vildagliptin for treatment of type 2 diabetes. |
| Q26748870 | The Association between Sulfonylurea Use and All-Cause and Cardiovascular Mortality: A Meta-Analysis with Trial Sequential Analysis of Randomized Clinical Trials |
| Q38527885 | The Place of Dipeptidyl Peptidase-4 Inhibitors in Type 2 Diabetes Therapeutics: A "Me Too" or "the Special One" Antidiabetic Class? |
| Q88312476 | The Vildagliptin Experience - 25 Years Since the Initiation of the Novartis Glucagon-like Peptide-1 Based Therapy Programme and 10 Years Since the First Vildagliptin Registration |
| Q37992253 | The design of the liraglutide clinical trial programme |
| Q39339957 | The effect of vildagliptin relative to sulfonylurea as dual therapy with metformin (or as monotherapy) in Muslim patients with type 2 diabetes fasting during Ramadan in the Middle East: the VIRTUE study |
| Q37970749 | The efficacy and safety of vildagliptin in patients with type 2 diabetes: a meta-analysis of randomized clinical trials |
| Q38137027 | The incidence of mild and severe hypoglycaemia in patients with type 2 diabetes mellitus treated with sulfonylureas: a systematic review and meta-analysis |
| Q38196747 | The long-term efficacy and safety of DPP-IV inhibitors monotherapy and in combination with metformin in 18,980 patients with type-2 diabetes mellitus--a meta-analysis |
| Q38212472 | Vildagliptin , a DPP-4 inhibitor for the twice-daily treatment of type 2 diabetes mellitus with or without metformin. |
| Q37801906 | Vildagliptin: a review of its use in type 2 diabetes mellitus |
| Q87461871 | Vildagliptin: a review of its use in type 2 diabetes mellitus |
| Q86976884 | Within-class differences of the sulfonylureas should be accounted for |
Search more.